HELICOMARK
Antibody-responses to Helicobacter pylori and tumour proteins as biomarkers for early gastric cancer
| Coordinatore | GOETEBORGS UNIVERSITET
Organization address
address: VASAPARKEN contact info |
| Nazionalità Coordinatore | Sweden [SE] |
| Totale costo | 390˙265 € |
| EC contributo | 390˙265 € |
| Programma | FP7-PEOPLE
Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013) |
| Code Call | FP7-PEOPLE-2013-IOF |
| Funding Scheme | MC-IOF |
| Anno di inizio | 2014 |
| Periodo (anno-mese-giorno) | 2014-09-01 - 2017-08-31 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
GOETEBORGS UNIVERSITET
Organization address
address: VASAPARKEN contact info |
SE (GOETEBORG) | coordinator | 390˙265.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'This proposal concerns an outgoing fellowship for Samuel Lundin (SL), PhD, Dept. of Microbiology and Immunology, University of Gothenburg. To further develop and substantially boost his scientific career, SL will for two years visit the laboratory of Professor Barry Marshall, University of Western Australia, Perth, Australia. SL has a good track record in science, but lacks crucial skills in bioinformatics and H. pylori genomics. The fellowship at the Marshall group will alleviate this and thereby allow SL to perform research at the top international level.
Gastric cancer is the second most common cause of cancer-related death worldwide, and is particularly prevalent in East Asia, Eastern Europe and Central and South America. This cancer type is caused by Helicobacter pylori, a bacterium that was discovered by the outgoing host Prof. Marshall.
The proposed research project aims to identify antibody signatures to Helicobacter pylori infection and tumour proteins as serological biomarkers for early gastric cancer. Such biomarkers would allow screening and early detection of gastric cancer, which most likely would lead to increased survival.
Therefore, this project has the potential to lead to a reduced mortality of gastric cancer, and it will also add significantly to European research and to the biotech industry.'